keyword
https://read.qxmd.com/read/38659705/erratum-effect-of-the-rock-inhibitor-fasudil-on-the-brain-proteomic-profile-in-the-tau-transgenic-mouse-model-of-alzheimer-s-disease
#1
(no author information available yet)
[This corrects the article DOI: 10.3389/fnagi.2024.1323563.].
2024: Frontiers in Aging Neuroscience
https://read.qxmd.com/read/38653998/molecular-subtype-identification-of-cerebral-ischemic-stroke-based-on-ferroptosis-related-genes
#2
JOURNAL ARTICLE
Yufeng Wang, Xinjuan Xu, Xinjun Shui, Ruilin Ren, Yu Liu
Cerebral ischemic stroke (CIS) has the characteristics of a high incidence, disability, and mortality rate. Here, we aimed to explore the potential pathogenic mechanisms of ferroptosis-related genes (FRGs) in CIS. Three microarray datasets from the Gene Expression Omnibus (GEO) database were utilized to analyze differentially expressed genes (DEGs) between CIS and normal controls. FRGs were obtained from a literature report and the FerrDb database. Weighted gene co-expression network analysis (WGCNA) and protein-protein interaction (PPI) network were used to screen hub genes...
April 23, 2024: Scientific Reports
https://read.qxmd.com/read/38597431/-restraint-stress-induces-blood-brain-barrier-injury-in-rat-amygdala-by-activating-the-rho-rock-signaling-pathway
#3
JOURNAL ARTICLE
G Xu, A Gao, B Cong
OBJECTIVE: To investigate the role of Rho/ROCK signaling pathway in mediating restraint stress-induced blood-brain barrier (BBB) injury in the amygdala of rats. METHODS: Sixty male SD rats were randomized equally into control group (with food and water deprivation for 6 h per day), restraint stress group (with restraint for 6 h per day), stress + fasudil treatment (administered by intraperitoneal injection at 1 mg/100 g 30 min before the 6-h restraint) group, and fasudil treatment alone group...
March 20, 2024: Nan Fang Yi Ke da Xue Xue Bao, Journal of Southern Medical University
https://read.qxmd.com/read/38561558/oligomeric-amyloid-%C3%AE-and-tau-alter-cell-adhesion-properties-and-induce-inflammatory-responses-in-cerebral-endothelial-cells-through-the-rhoa-rock-pathway
#4
JOURNAL ARTICLE
Faruk Hossen, Xue Geng, Grace Y Sun, Xincheng Yao, James C Lee
Dysfunction of cerebral endothelial cells (CECs) has been implicated in the pathology of Alzheimer's disease (AD). Despite evidence showing cytotoxic effects of oligomeric amyloid-β (oAβ) and Tau (oTau) in the central nervous system, their direct effects on CECs have not been fully investigated. In this study, we examined the direct effects of oAβ, oTau, and their combination on cell adhesion properties and inflammatory responses in CECs. We found that both oAβ and oTau increased cell stiffness, as well as the p-selectin/Sialyl-LewisX (sLeX ) bonding-mediated membrane tether force and probability of adhesion in CECs...
April 2, 2024: Molecular Neurobiology
https://read.qxmd.com/read/38538716/rock1-inhibition-improves-wound-healing-in-diabetes-via-ripk4-ampk-pathway
#5
JOURNAL ARTICLE
Tianru Huyan, Lu Fan, Zhong-Yuan Zheng, Jing-Hui Zhao, Zhen-Ru Han, Pin Wu, Qun Ma, Ya-Qin Du, Yun-di Shi, Chun-Yan Gu, Xue-Jun Li, Wen-Hui Wang, Long Zhang, Lu Tie
Refractory wounds are a severe complication of diabetes mellitus that often leads to amputation because of the lack of effective treatments and therapeutic targets. The pathogenesis of refractory wounds is complex, involving many types of cells. Rho-associated protein kinase-1 (ROCK1) phosphorylates a series of substrates that trigger downstream signaling pathways, affecting multiple cellular processes, including cell migration, communication, and proliferation. The present study investigated the role of ROCK1 in diabetic wound healing and molecular mechanisms...
March 27, 2024: Acta Pharmacologica Sinica
https://read.qxmd.com/read/38533144/successful-fluid-management-in-respiratory-failure-due-to-clazosentan-following-a-cerebral-aneurysm-clipping-a-case-report
#6
Hirotaka Kinoshita, Kodai Kato, Yuma Yamazaki, Eiji Hashiba, Kazuyoshi Hirota
Clazosentan, a potent selective endothelin receptor subtype A antagonist, has been demonstrated to be effective in preventing cerebral vasospasms after subarachnoid hemorrhage. We report the successful management of respiratory failure due to pulmonary edema associated with clazosentan, with a hemodynamic monitoring system. A 49-year-old Japanese man underwent emergency clipping for a right internal carotid-posterior communicating artery aneurysm. The surgery and general anesthesia for the rupture proceeded with no complications...
February 2024: Curēus
https://read.qxmd.com/read/38513591/-keep-on-rockin-repurposed-rock-inhibitors-to-boost-corneal-endothelial-regeneration
#7
JOURNAL ARTICLE
Hendrik Vercammen, Martin Ondra, Jana Kotulova, Edgar Cardenas De La Hoz, Charissa Witters, Katerina Jecmenova, Maxim Le Compte, Christophe Deben, Sorcha Ní Dhubhghaill, Carina Koppen, Marián Hajdúch, Bert Van den Bogerd
The global shortage of corneal endothelial graft tissue necessitates the exploration of alternative therapeutic strategies. Rho-associated protein kinase inhibitors (ROCKi), recognized for their regenerative potential in cardiology, oncology, and neurology, have shown promise in corneal endothelial regeneration. This study investigates the repurposing potential of additional ROCKi compounds. Through screening a self-assembled library of ROCKi on B4G12 corneal endothelial cells, we evaluated their dose-dependent effects on proliferation, migration, and toxicity using live-cell imaging...
March 20, 2024: Biomedicine & Pharmacotherapy
https://read.qxmd.com/read/38479593/evaluation-of-the-translation-of-multiple-cardiovascular-regulatory-mechanisms-in-the-anesthetized-dog
#8
JOURNAL ARTICLE
Olivera Antic, Yevgeniya E Koshman, Brandan M Bird, Geena Jasiek, Amanda S Wilsey, Scott W Mittelstadt, C Michael Foley
The strategic and targeted use of an anesthetized canine cardiovascular model early in drug discovery enables a comprehensive cardiovascular and electrophysiological assessment of potential safety liabilities and guides compound selection prior to initiation of chronic toxicological studies. An ideal model would enable exposure-response relationships to guide safety margin calculations, have a low threshold to initiate, and have quick delivery of decision quality data. We have aimed to profile compounds with diverse mechanism of actions (MoAs) of "non-QT" cardiovascular drug effects and evaluate the ability of nonclinical in vivo cardiovascular models to detect clinically reported effects...
March 11, 2024: Journal of Pharmacological and Toxicological Methods
https://read.qxmd.com/read/38472507/comparison-of-efficacy-between-clazosentan-and-fasudil-hydrochloride-based-management-of-vasospasm-after-subarachnoid-hemorrhage-focusing-on-older-and-wfns-grade-v-patients-a-single-center-experience-in-japan
#9
RANDOMIZED CONTROLLED TRIAL
Tatsuki Mochizuki, Bikei Ryu, Shogo Shima, Eriko Kamijyo, Koki Ito, Tamon Ando, Kazuki Kushi, Shinsuke Sato, Tatsuya Inoue, Akitsugu Kawashima, Takakazu Kawamata, Yoshikazu Okada, Yasunari Niimi
Subarachnoid hemorrhage often leads to poor outcomes owing to vasospasm, even after successful aneurysm treatment. Clazosentan, an endothelin receptor inhibitor, has been proven to be an effective treatment for vasospasms in a Japanese randomized controlled trial. However, its efficacy in older patients (≥ 75 years old) and those with World Federation of Neurosurgical Societies (WFNS) grade V has not been demonstrated. We retrospectively evaluated the efficacy of clazosentan in older patients and those with WFNS grade V, using real-world data...
March 13, 2024: Neurosurgical Review
https://read.qxmd.com/read/38440100/effect-of-the-rock-inhibitor-fasudil-on-the-brain-proteomic-profile-in-the-tau-transgenic-mouse-model-of-alzheimer-s-disease
#10
JOURNAL ARTICLE
Roberto Collu, Zheng Yin, Elisa Giunti, Sarah Daley, Mei Chen, Peter Morin, Richard Killick, Stephen T C Wong, Weiming Xia
INTRODUCTION: The goal of this study is to explore the pharmacological potential of the amyloid-reducing vasodilator fasudil, a selective Ras homolog (Rho)-associated kinases (ROCK) inhibitor, in the P301S tau transgenic mouse model (Line PS19) of neurodegenerative tauopathy and Alzheimer's disease (AD). METHODS: We used LC-MS/MS, ELISA and bioinformatic approaches to investigate the effect of treatment with fasudil on the brain proteomic profile in PS19 tau transgenic mice...
2024: Frontiers in Aging Neuroscience
https://read.qxmd.com/read/38419648/protocol-for-a-randomized-placebo-controlled-double-blind-phase-iia-study-of-the-safety-tolerability-and-symptomatic-efficacy-of-the-rock-inhibitor-fasudil-in-patients-with-parkinson-s-disease-rock-pd
#11
JOURNAL ARTICLE
Andreas W Wolff, Helen Bidner, Yvonne Remane, Janine Zimmer, Dag Aarsland, Olivier Rascol, Richard K Wyse, Alexander Hapfelmeier, Paul Lingor
BACKGROUND: The Rho-kinase (ROCK) inhibitor Fasudil has shown symptomatic and disease-modifying effects in Parkinson's disease (PD) models in vitro and in vivo . In Japan, Fasudil has been approved for the treatment of subarachnoid haemorrhage since 1995 and shows a favourable safety profile. OBJECTIVES/DESIGN: To investigate the safety, tolerability, and symptomatic efficacy of ROCK-inhibitor Fasudil in comparison to placebo in a randomized, national, multicenter, double-blind phase IIa study in patients with PD...
2024: Frontiers in Aging Neuroscience
https://read.qxmd.com/read/38416402/safe-rock-a-phase-i-trial-of-an-oral-application-of-the-rock-inhibitor-fasudil-to-assess-bioavailability-safety-and-tolerability-in-healthy-participants
#12
RANDOMIZED CONTROLLED TRIAL
Andreas W Wolff, Jörg Peine, Josef Höfler, Gabriela Zurek, Claus Hemker, Paul Lingor
BACKGROUND: The intravenous (IV) formulation of Rho-kinase (ROCK) inhibitor fasudil has been approved for the treatment of subarachnoid haemorrhage since 1995. Additionally, fasudil has shown promising preclinical results for various chronic diseases, including neurodegenerative diseases such as amyotrophic lateral sclerosis, Parkinson's disease, and dementia, in which long-term intravenous (IV) administration might not be suitable. OBJECTIVE: The objective of this study was to assess the absolute bioavailability of oral, in comparison to IV, application of the approved formulation of fasudil (ERIL®) and to evaluate the safety and tolerability of the oral application of fasudil...
April 2024: CNS Drugs
https://read.qxmd.com/read/38379356/-baihui-du20-penetrating-qubin-gb7-acupuncture-on-blood-brain-barrier-integrity-in-rat-intracerebral-hemorrhage-models-via-the-rhoa-rock-ii-mlc-2-signaling-pathway
#13
JOURNAL ARTICLE
Ce Zhang, Jia Zheng, Xueping Yu, Binglin Kuang, Xiaohong Dai, Lei Zheng, Weiwei Yu, Wei Teng, Hongtao Cao, Mingyue Li, Jiayong Yao, Xiaoying Liu, Wei Zou
BACKGROUND: Blocking the RhoA/ROCK II/MLC 2 (Ras homolog gene family member A/Rho kinase II/myosin light chain 2) signaling pathway can initiate neuroprotective mechanisms against neurological diseases such as stroke, cerebral ischemia, and subarachnoid hemorrhage. Nevertheless, it is not clear whether and how disrupting the RhoA/ROCK II/MLC 2 signaling pathway changes the pathogenic processes of the blood-brain barrier (BBB) after intracerebral hemorrhage (ICH). The present investigation included the injection of rat caudal vein blood into the basal ganglia area to replicate the pathophysiological conditions caused by ICH...
February 20, 2024: Animal Models and Experimental Medicine
https://read.qxmd.com/read/38345441/radial-artery-spasms-impair-invasive-cardiological-procedures-performance-a-pharmacological-approach-to-prevention-and-treatment
#14
JOURNAL ARTICLE
M Chyrchel, J Roczniak, A Surdacki
The radial artery (RA) access is currently the gold standard to perform cardiovascular interventions. One of the more common limitations is radial artery spasm which is an often complication interrupting the procedure. Common risk factors associated with spasm include female gender, periprocedural anxiety, multiple puncture attempts, distal radial access, diabetes, hypertension, and smoking. The mechanism of spasm is complex and includes calmodulin and rho-kinase pathways leading to the smooth muscle contraction...
December 2023: Journal of Physiology and Pharmacology: An Official Journal of the Polish Physiological Society
https://read.qxmd.com/read/38309665/early-chronic-fasudil-treatment-rescues-hippocampal-alterations-in-the-ts65dn-model-for-down-syndrome
#15
JOURNAL ARTICLE
Rosa López-Hidalgo, Raúl Ballestín, Lorena Lorenzo, Sandra Sánchez, José Miguel Blasco-Ibáñez, Carlos Crespo, Juan Nacher, Emilio Varea
Down syndrome (DS) is the most common genetic disorder associated with intellectual disability. To study this syndrome, several mouse models have been developed. Among the most common is the Ts65Dn model, which mimics most of the alterations observed in DS. Ts65Dn mice, as humans with DS, show defects in the structure, density, and distribution of dendritic spines in the cerebral cortex and hippocampus. Fasudil is a potent inhibitor of the RhoA kinase pathway, which is involved in the formation and stabilization of dendritic spines...
February 1, 2024: Neurochemistry International
https://read.qxmd.com/read/38280440/identification-of-fasudil-as-a-collaborator-to-promote-the-anti-tumor-effect-of-lenvatinib-in-hepatocellular-carcinoma-by-inhibiting-gli2-mediated-hedgehog-signaling-pathway
#16
JOURNAL ARTICLE
Yilan Huang, Siwei Wang, Xiaojun Zhang, Chen Yang, Sikai Wang, Hongxia Cheng, Aiwu Ke, Chao Gao, Kun Guo
Lenvatinib is a frontline tyrosine kinase inhibitor for patients with advanced hepatocellular carcinoma (HCC). However, just 25% of patients benefit from the treatment, and acquired resistance always develops. To date, there are neither effective medications to combat lenvatinib resistance nor accurate markers that might predict how well a patient would respond to the lenvatinib treatment. Thus, novel strategies to recognize and deal with lenvatinib resistance are desperately needed. In the current study, a robust Lenvatinib Resistance index (LRi) model to predict lenvatinib response status in HCC was first established...
January 25, 2024: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://read.qxmd.com/read/38264539/the-role-of-rho-kinase-inhibitors-in-corneal-diseases
#17
REVIEW
Stefan Futterknecht, Eleftherios Chatzimichail, Konstantin Gugleta, Georgios D Panos, Zisis Gatzioufas
The cornea, as the outermost layer of the eye, plays a crucial role in vision by focusing light onto the retina. Various diseases and injuries can compromise its clarity, leading to impaired vision. This review aims to provide a thorough overview of the pharmacological properties, therapeutic potential and associated risks of Rho-associated protein kinase (ROCK) inhibitors in the management of corneal diseases. The article focuses on four key ROCK inhibitors: Y-27632, fasudil, ripasudil, and netarsudil, providing a comparative examination...
2024: Drug Design, Development and Therapy
https://read.qxmd.com/read/38258122/exploring-the-ocular-absorption-pathway-of-fasudil-hydrochloride-towards-developing-a-nanoparticulate-formulation-with-improved-performance
#18
JOURNAL ARTICLE
Barzan Osi, Ali A Al-Kinani, Zinah K Al-Qaysi, Mouhamad Khoder, Raid G Alany
Rho-kinase (ROCK) inhibitors represent a new category of anti-glaucoma medications. Among them, Fasudil hydrochloride, a selective ROCK inhibitor, has demonstrated promising outcomes in glaucoma treatment. It works by inhibiting the ROCK pathway, which plays a crucial role in regulating the trabecular meshwork and canal of Schlemm's aqueous humor outflow. This study aims to investigate the ocular absorption pathway of Fasudil hydrochloride and, subsequently, develop a nanoparticle-based delivery system for enhanced corneal absorption...
January 15, 2024: Pharmaceutics
https://read.qxmd.com/read/38243987/pharmacotherapy-in-sah-clinical-trial-lessons
#19
JOURNAL ARTICLE
Sotirios Apostolakis, Pantelis Stavrinou
Subarachnoid Haemorrhage (SAH) is a medical emergency with potentially devastating outcomes. It is without doubt that over the past decades, there has been a radical change in the approach towards patients with SAH, both in terms of the surgical as well as of the pharmacological treatments offered. The present review aims to outline the principal data regarding the best practice in the pharmacotherapy of SAH, as well as to sum up the emerging evidence from the latest clinical trials. To date, nimodipine is the only evidence-based treatment of vasospasm...
January 15, 2024: CNS & Neurological Disorders Drug Targets
https://read.qxmd.com/read/38222788/empagliflozin-ameliorates-diabetic-cardiomyopathy-probably-via-activating-ampk-pgc-1%C3%AE-and-inhibiting-the-rhoa-rock-pathway
#20
JOURNAL ARTICLE
Na Li, Qiu-Xiao Zhu, Gui-Zhi Li, Ting Wang, Hong Zhou
BACKGROUND: Diabetic cardiomyopathy (DCM) increases the risk of hospitalization for heart failure (HF) and mortality in patients with diabetes mellitus. However, no specific therapy to delay the progression of DCM has been identified. Mitochondrial dysfunction, oxidative stress, inflammation, and calcium handling imbalance play a crucial role in the pathological processes of DCM, ultimately leading to cardiomyocyte apoptosis and cardiac dysfunctions. Empagliflozin, a novel glucose-lowering agent, has been confirmed to reduce the risk of hospitalization for HF in diabetic patients...
December 15, 2023: World Journal of Diabetes
keyword
keyword
39154
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.